Cite
HARVARD Citation
Adams, R. et al. (2018). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet gastroenterology and hepatology. pp. 162-171. [Online].